Understanding Alzheimer's Disease

Prevention is often more effective than treatment, especially considering the absence of a cure for Alzheimer's disease.

In recent years, the focus on COVID-19 vaccines has overshadowed other medical advancements. However, researchers from Switzerland and Belgium have made significant strides toward creating a vaccine aimed at preventing Alzheimer's disease.

Overview of Alzheimer's Disease

Alzheimer's disease is the leading cause of dementia, responsible for 60-80% of cases, which affects around 6.2 million older adults in the U.S. and at least 44 million globally. This condition is characterized by the death of neurons in the brain and is primarily driven by two pathological features: amyloid plaques and neurofibrillary tangles.

Amyloid plaques consist of clumps of a protein known as amyloid beta, which form outside neurons and disrupt their communication. Neurofibrillary tangles, on the other hand, are formed by tau proteins that aggregate inside neurons, obstructing the transport of essential cellular materials. As neurons fail to function properly, they eventually die, leading to brain shrinkage and symptoms of dementia, such as memory loss and confusion.

To prevent Alzheimer's, it is crucial to inhibit the formation of both amyloid plaques and neurofibrillary tangles.

The Formation of Plaques and Tangles

The genesis of these plaques and tangles begins with the Amyloid Precursor Protein (APP), located in neuronal membranes and vital for neuronal growth and repair. Over time, APP needs to be replaced, but it must first be broken down and removed.

Outside the Neurons

The body uses two primary pathways to degrade APP:

• Non-amyloidogenic Pathway: APP is cleaved into smaller, soluble fragments that can be easily eliminated.
• Amyloidogenic Pathway: APP is cleaved into insoluble fragments, including amyloid beta (Aβ), which are more challenging to remove.

In Alzheimer's patients, the production of Aβ surpasses its elimination, leading to its accumulation and subsequent plaque formation, which hinders neuronal signaling.

Inside the Neurons

Microtubules, essential for transporting materials within neurons, are stabilized by tau proteins. In Alzheimer's, Aβ disrupts this stability, causing tau proteins to detach and aggregate, forming neurofibrillary tangles.

Consequently, focusing on the removal of Aβ is critical for preventing Alzheimer's disease.

Development of the Amyloid-Beta Vaccine

Vaccines are designed to provoke an immune response by introducing a part or whole pathogen. In a recent study published in Brain Communications, researchers have created a vaccine that activates the body's immune system to target and eliminate toxic Aβ.

Research Methodology

The team utilized a truncated version of Aβ, consisting of just the first 15 amino acids, as the peptide for their vaccine, named "ACI-24." They conducted trials by administering two doses to ten female mice and five doses to four monkeys over a period, monitoring immune responses through blood samples collected before and after vaccinations.

Findings

One week post-vaccination, all mice demonstrated a robust antibody response against full-length Aβ, with the majority producing high levels of antibodies capable of binding to neurotoxic versions of Aβ. The monkeys also exhibited a strong antibody response.

They observed that the vaccine was well-tolerated, with only minor local reactions at injection sites.

Broad Recognition and Previous Challenges

The researchers conducted epitope mapping to identify the specific sites on Aβ where antibodies bind, discovering that the vaccine prompts a wide recognition pattern of various Aβ sequences.

Limitations of Earlier Vaccines

ACI-24 builds upon previous vaccines like AN1792 and ACC-100, which faced challenges such as adverse inflammatory reactions and inadequate immune responses. AN1792 was halted due to severe inflammation in participants, while ACC-100 failed to demonstrate significant cognitive benefits despite being well tolerated.

Enhancements in Vaccine Design

The first 15 amino acids of Aβ, used in ACI-24, effectively stimulate B-cells without activating T-cells, circumventing inflammation while promoting broader antibody diversity. The delivery system of the peptide was also improved, mimicking the pathological form of Aβ to enhance immunogenicity.

Moreover, the inclusion of a sequence similar to those found in disease-causing microorganisms helps activate helper T-cells, facilitating a more effective immune response without risking inflammatory reactions.

The researchers concluded that ACI-24 provides a safe and effective alternative to expensive monoclonal antibody therapies, with clinical testing for the optimized formulation expected to begin soon.

Conclusion

Alzheimer's disease is primarily caused by amyloid plaques and neurofibrillary tangles, leading to neuronal death and brain atrophy. Preventing the accumulation of amyloid beta proteins is essential for combating this disease. The promising development of the ACI-24 vaccine represents a significant advancement, potentially overcoming the limitations of earlier attempts and paving the way for effective prevention strategies.

Thank you for your attention. If you appreciate this content, consider subscribing to my Medium email list for updates. For unlimited access to Medium articles, join using my referral link—your support is appreciated!

The first video discusses how neurotoxin research could pave the way for vaccines against Alzheimer's disease, shedding light on innovative approaches to prevention.

The second video explores the question of whether Alzheimer's can truly be prevented, featuring insights from experts in the field.